Robert Lagier
Celera Corporation
17 Papers
164 Citations
Robert Lagier is an academic researcher from Celera Corporation. The author has contributed to research in topics: Cirrhosis & Population. The author has an hindex of 8, co-authored 16 publications. Previous affiliations of Robert Lagier include Chiron Corporation.
Chat about Author
Papers
Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.
Jill Detmer,Robert Lagier,J Flynn,C Zayati,Janice A. Kolberg,Mark L. Collins,Mickey S. Urdea,Ray Sanchez-Pescador +7 more
TL;DR: The improved branched DNA assay (HCV RNA 2.0) yielded highly reproducible quantification of hepatitis C virus RNA and displayed a nearly 600-fold dynamic range in quantification up to 120 Meq of HCV RNA per ml.
237
Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA.
Harvey J. Alter,Ray Sanchez-Pescador,Mickey S. Urdea,Judith C. Wilber,Robert Lagier,A. M. Di Bisceglie,James Wai-Kuo Shih,Paul Neuwald +7 more
TL;DR: This study evaluates branched DNA (bDNA) signal amplification, a technique that avoids many of the pitfalls of polymerase chain reaction (PCR), to assess the viral burden in chronic hepatitis C virus infection.
102
Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort
Jacob Alexander Lykke,Lance A. Bare,Jørn Olsen,Jørn Olsen,Robert Lagier,Andre R. Arellano,Carmen H. Tong,Michael J. Paidas,Jens Langhoff-Roos +8 more
TL;DR: Differences in study design, size and population could explain this heterogeneity, and Inherited thrombophilias have inconsistently been linked to adverse pregnancy outcomes.
84
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).
Teresa M. Curto,Robert Lagier,Anna S. Lok,James E. Everhart,Charles M. Rowland,John J. Sninsky +5 more
TL;DR: CRS7 was validated as a predictor of fibrosis progression and cirrhosis among Hepatitis C Antiviral Long-term Treatment against Cirrhosis patients, who all had advanced fibrosis, and was not predictive of clinical outcome.
Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease.
Yonghong Li,Charles M. Rowland,Georgia Xiromerisiou,Robert Lagier,Steven J. Schrodi,Efthimios Dradiotis,David Ross,Nam Bui,Joseph J. Catanese,Konstantinos Aggelakis,Andrew Grupe,Georgios M. Hadjigeorgiou,Georgios M. Hadjigeorgiou +12 more
TL;DR: Together, these results challenge the robustness of the reported panel of genetic markers to predict PD risk in particular and a role of the axon guidance pathway in PD genetics in general.